Scenarios that move MDGL
Madrigal Pharmaceuticals, Inc. - Common Stock
Scenarios that move MDGL: 4 analyses, 2 positive, 2 negative.
- · Syndax stock falls 16% as Phase II fibrosis study misses primary goal — ▼ · impact -30 · confidence low · horizon quarters
- · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▲ · impact +15 · confidence low · horizon immediate
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▼ · impact -26 · confidence low · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▲ · impact +32 · confidence low · horizon weeks